NL-OMON33355
Not yet recruiting
Not Applicable
Pharmacogenomics of anthracycline-induced cardiotoxicity in children with cancer - Pharmacogenomics and anthracycline cardiotoxicity
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 80
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational invasive
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Diagnosis of childhood cancer and treatment with anthracyclines
- •Decreased heart function and normal heart function
- •Age: at least 18 years old
Exclusion Criteria
- •Age: below 18 years
Investigators
Similar Trials
Completed
Not Applicable
A cohort study of anthracycline-induced cardiotoxicityAll patients scheduled for anthracycline-containing therapy for various kinds of tumorsJPRN-UMIN000022984niversity of Tsukuba500
Completed
Not Applicable
Early Cardiac Changes During Chemotherapy in Breast CancerChemotherapy induced CardiomyopathyBreast CancerCardiovascular - Other cardiovascular diseasesCancer - BreastACTRN12611000153910Professor Joseph Selvanayagam100
Completed
Not Applicable
Can we detect early chemotherapy related heart damage in patients with lymphoma using advanced echocardiography?ISRCTN84544539South Tees NHS Foundation Trust45
Active, not recruiting
Not Applicable
Prevention of anthracycline-induced cardiotoxicity: a multicentre randomizedtrial comparing two therapeutic strategies.EUCTR2012-002248-26-ITISTITUTO EUROPEO DI ONCOLOGIA
Completed
Not Applicable
Primary Prevention of Anthracycline-induced Cardiotoxicity with L-Carnitine in patients with breast Cancer (PPACC): pilot studyBreast CancerCancerISRCTN32332192niversity of Ottawa Heart Institute (Institut de cardiologie de l'Université d'Ottawa) (Canada)144